Journal of Clinical Oncology
Articles in this Issue
In-hospital outcomes of radiation pneumonitis and drug-induced pneumonitis in patients with breast cancer.
e23087 Background: Pneumonitis represents a significant adverse event among breast cancer patients undergoing advanced therapies, including immune checkpo...
Evaluating accuracy and concordance of pathologists and the utility of AI assistance software for digital HER2 IHC assessment in breast cancer including HER2-ultralow scoring: An international multicenter observational study.
1078 Background: The emergence of novel therapeutic agents demonstrating improved progression-free survival (PFS) and overall survival (OS) in breast canc...
Outcomes in patients (pts) younger than 50 years old (yo) with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subanalysis of a phase 1/2 trial.
6518 Background: BPDCN is an aggressive, orphan hematologic malignancy characterized by cells expressing CD123 and other markers. In BPDCN pts <50 yo,...
Enhancing colorectal cancer precision medicine through multi-omics and clinical data integration with artificial intelligence.
3603 Background: The integration of multi-omics and clinical data in precision medicine research for colorectal cancer (CRC) is a complex task that requir...
PhaseX: Patient tumor avatars for evaluating anticancer therapeutics.
2657 Background: Current preclinical tumor platforms, such as in vitro 2D cell cultures and organoid models, fail to fully recapitulate the complexity of...
Impact of lymph node dissection on prognosis in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemotherapy and immunotherapy followed by radical surgery.
e16149 Background: Currently, neoadjuvant chemoimmunotherapy (nCIT) is widely used in the perioperative treatment of esophageal squamous cell carcinoma (E...
Non-small cell lung cancer in women: Experience of the National Institute of Oncology of Rabat, Morocco.
e20633 Background: Lung cancer is the leading cause of cancer deaths worldwide; its incidence in the female population is increasing. The objective of thi...
Exploration on perioperative treatment strategies of driver gene–positive resectable non-small cell lung cancer.
e20071 Background: In recent years, multiple neoadjuvant treatment options have emerged for driver gene–positive, resectable Non-Small Cell Lung Cancer (N...
Mechanism study of reversing tumor immune desertification and immunotherapy resistance by low dose radiotherapy.
e15181 Background: The immune classification of tumor can be divided into immune infiltrating type, immune rejection type and immune desert type. There is...
Fusing quality improvement and education frameworks to reduce delays in tumor genotyping at community cancer centers.
e23238 Background: Delays in obtaining tumor genotyping results hinder the ability of community-based oncologists to develop timely and effective treatmen...
Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial.
5517 Background: This report presents an update results of the BAT-8006-001-CR trial, which evaluated the safety and clinical activity of BAT8006, an anti...
Analyses of clinical and biologic determinants of melanoma bone metastasis (Mel-Bone).
e21503 Background: Mel-Bone represents a clinical challenge due to its known association with pain and pathological fractures. While bone metastases occur...
Phase 2 study of DZD8586, a non-covalent BBB penetrant LYN/BTK dual inhibitor, as monotherapy in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL; TAI-SHAN9).
e19050 Background: Diffuse large B-cell lymphoma (DLBCL) is a phenotypically and genetically heterogeneous disease with unmet medical needs. The therapeut...
Personalized tumor-informed circulating tumor DNA analysis in monitoring recurrence following resection of high-risk locally advanced stage gastrointestinal stromal tumor.
11522 Background: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Radical resection is the stand...
Final patient-reported outcomes (PROs) in unselected men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as initial treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from the phase 3 TALAPRO-2 study.
11120 Background: TALAPRO-2 demonstrated statistically significant improvement with TALA + ENZA vs PBO + ENZA in radiographic progression-free survival (p...
IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with R/R STS: A phase Ib expansion study.
11545 Background: IMM2510 is a novel bispecific antibody fusion protein targeting PD-L1 and VEGF. The results of dose-escalation phase were previously rep...
Combination of mitoxantrone hydrochloride liposome with tislelizumab in patients with relapsed or refractory NK/T cell lymphoma: A phase Ib/II study.
7055 Background: Natural killer/T-cell lymphoma (NKTCL) is a unique subtype of non-Hodgkin lymphoma with aggressive disease course. Mitoxantrone hydrochlo...
Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study.
9515 Background: Lifileucel is a personalized, one-time tumor-derived autologous T-cell immunotherapy approved for the treatment of adult patients (pts) w...
The addition of monoclonal antibodies to chemotherapy in metastatic early-onset colorectal cancer: A comparative effectiveness study using real-world data.
e15580 Background: The incidence of early-onset colorectal cancer (eoCRC) in adults under the age of 50 years is rising in Canada and the United States. D...
A process evaluation trial of a telehealth service intervention to support uptake of breast cancer prevention medications.
TPS10623 Background: Breast cancer prevention medications (BCPrevMeds), such as tamoxifen and anastrozole, halve breast cancer (BC) risk. Our prior resear...
Impact of patient frailty on the choice of induction treatment for transplant-ineligible (TIE) newly diagnosed (ND) multiple myeloma (MM).
e19561 Background: One of the major factors influencing the choice of triplet versus quadruplet therapies in TIE ND MM is performance status (i.e., patien...
Unveiling drivers of MHC repression and therapeutic strategies to counter immune evasion in small cell lung cancer.
8091 Background: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy with a median survival of 9–11 months. Despite the additio...
Assessment of plasma ctDNA mutational profile and heterogeneity in renal cell carcinoma patients.
e14544 Background: Renal cell carcinoma (RCC) is a common form of kidney cancer that presents significant challenges in both diagnosis and treatment. Desp...
Combination ipilimumab/nivolumab for refractory Merkel cell carcinoma: A single-institution experience.
e21528 Background: Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine tumor with an aggressive disease course. Many patients will recur or pro...
A real-world study of the NALIRIFOX regimen in perioperative treatment of borderline resectable and locally advanced pancreatic cancer in China.
e16450 Background: Pancreatic cancer is a highly aggressive malignancy with poor prognosis, with only approximately 10% of patients eligible for immediate...